paclitaxel has been researched along with Retinal Neovascularization in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Breen, S; Chang, Y; Coats, S; Coffman, K; Czapiga, M; Fazenbaker, C; Gingles, N; Inigo, I; Jallal, B; Lavallee, T; Leow, CC; Peterson, N; Ricketts, SA; Soukharev, S; Woods, R | 1 |
1 other study(ies) available for paclitaxel and Retinal Neovascularization
Article | Year |
---|---|
MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Topics: Angiogenesis Inhibitors; Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Corrosion Casting; Dose-Response Relationship, Drug; Female; Fluorescence; HEK293 Cells; Humans; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Phosphorylation; Receptor, TIE-2; Retinal Neovascularization; Time Factors; Transfection; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2012 |